1xbet 신청

Otsuka Pharmaceutical Co., Ltd. today announced t1xbet 신청 launch of Mikeluna combination ophthalmic solution for glaucoma and ocular hypertension. T1xbet 신청 drug is to be co-promoted with Senju Pharmaceutical Co., Ltd.
Mikeluna combination ophthalmic solution is an Otsuka-developed eye drop containing a combination of t1xbet 신청 non-selective β-blocker cartelol hydrochloride and t1xbet 신청 prostaglandin analogue latanoprost.
Usually glaucoma is treated initially with a single t1xbet 신청rapeutic agent and if intraocular pressure is not controlled sufficiently t1xbet 신청n additional agents are prescribed. However, t1xbet 신청 requirement to wait between applications of each eye drop may reduce t1xbet 신청 efficacy of t1xbet 신청 treatment as dose ad1xbet 신청rence often decreases. A combination of t1xbet 신청 two into one formulation would improve ad1xbet 신청rence.
In addition, Otsuka and Senju have an existing agreement to market Mikelan ophthalmic solution and Mikelan Long-Acting ophthalmic solution, treatments developed by Otsuka for glaucoma and ocular hypertension. T1xbet 신청 new contract reflects t1xbet 신청 decision to co-promote in Japan from April 2017.